Search results
21 lut 2023 · This individual patient data meta-analysis showed that remdesivir reduced mortality in patients hospitalised with COVID-19 who required no or conventional oxygen support, but was underpowered to evaluate patients who were ventilated when receiving remdesivir.
22 maj 2020 · Remdesivir (GS-5734), an inhibitor of the viral RNA-dependent, RNA polymerase with in vitro inhibitory activity against SARS-CoV-1 and the Middle East respiratory syndrome (MERS-CoV), 5-8 was...
22 gru 2021 · Remdesivir improves clinical outcomes in patients hospitalized with moderate-to-severe coronavirus disease 2019 (Covid-19). Whether the use of remdesivir in symptomatic, nonhospitalized...
Najważniejsze informacje. • U dorosłych hospitalizowanych z powodu COVID-19, stosowanie remdesiwiru, w porównaniu z placebo (leczeniem pozorowanym) lub standardową opieką, ma prawdopodobnie niewielki lub żaden wpływ na ryzyko zgonu w ciągu 150 dni od rozpoczęcia leczenia.
Is remdesivir (an antiviral medicine) an effective treatment for COVID‐19? Key messages • For adults hospitalised with COVID‐19, remdesivir probably has little or no effect on deaths from any cause up to 28 days after treatment compared with placebo (sham treatment) or usual care.
Despite conditional recommendation against its use, remdesivir could still be effective in early clinical improvement; reduction of early mortality and avoiding high-flow supplemental oxygen and invasive mechanical ventilation among hospitalised COVID-19 patients.
27 maj 2020 · Remdesivir is an RNA polymerase inhibitor with potent antiviral activity in vitro and efficacy in animal models of coronavirus disease 2019 (Covid-19). We conducted a randomized,...
